Vatalanib (PTK787) is potent, orally available class III receptor tyrosine kinases inhibitor with IC50 of <1 uM for VEGFR, Flt-1, KDR and PDGFRβ.
Vatalanib (PTK787) shows no activity against EGFR, FGFR-1, c-Met, and Tie-2, or c-Src, c-Abl, and PKC-α.
Vatalanib (PTK787) blocks the VEGF-induced receptor autophosphorylation in CHO cells ectopically expressing the KDR receptor with IC50 of 34 nM.
Vatalanib (PTK787) inhibits EGF and PDGF-induced angiogenesis in a growth factor implant model (25-100 mg/kg).
